USANA Health Sciences (USNA) Stock Price, News & Analysis

Company Overview

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $27.29 to $28.18
• 50-Day Range: $26.21 to $34.96
• 52-Week Range: $26.19 to $49.78
• Volume: 192,585 shs
• Average Volume: 107,831 shs
• Market Capitalization: $532.18 million
• P/E Ratio: 9.95
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Hold

USANA Health Sciences Stock Analysis - MarketRank™

USANA Health Sciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 98th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

USANA Health Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

USANA Health Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 17.96%

Earnings Growth

Earnings for USANA Health Sciences are expected to grow by 17.96% in the coming year, from $2.45 to $2.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of USANA Health Sciences is 9.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of USANA Health Sciences is 9.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.14.

Price to Earnings Growth Ratio

USANA Health Sciences has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

USANA Health Sciences has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.62% of the float of USANA Health Sciences has been sold short.

Short Interest Ratio / Days to Cover

USANA Health Sciences has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in USANA Health Sciences has recently decreased by 0.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

USANA Health Sciences does not currently pay a dividend.

Dividend Growth

USANA Health Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.1 / 5
• Environmental Score: -2.10

Percentage of Shares Shorted

7.62% of the float of USANA Health Sciences has been sold short.

Short Interest Ratio / Days to Cover

USANA Health Sciences has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in USANA Health Sciences has recently decreased by 0.08%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.41

News Sentiment

USANA Health Sciences has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for USANA Health Sciences this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added USANA Health Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $500,285.00 in company stock.

Percentage Held by Insiders

Only 0.33% of the stock of USANA Health Sciences is held by insiders.

Percentage Held by Institutions

54.25% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

USNA Stock Analysis - Frequently Asked Questions

How have USNA shares performed this year?

USANA Health Sciences' stock was trading at $35.89 on January 1st, 2025. Since then, USNA stock has decreased by 21.6% and is now trading at $28.15.
View the best growth stocks for 2025 here.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings results on Tuesday, February, 25th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a trailing twelve-month return on equity of 10.64%.

Who are USANA Health Sciences' major shareholders?

Top institutional investors of USANA Health Sciences include Vanguard Group Inc. (8.11%), Renaissance Technologies LLC (5.72%), Pzena Investment Management LLC (5.70%) and Dimensional Fund Advisors LP (4.06%). Insiders that own company stock include Myron W Wentz, Jim Brown, David Mulham Mulham, Kevin Guest, John Turman Fleming, Peggie Pelosi, Frederic J Winssinger, Xia Ding, Joshua Foukas, Brent Neidig, Daniel A Macuga, G Doug Iiekking, Gilbert A Fuller, Robert A Sinnott, Walter Noot and Paul A Jones.
View institutional ownership trends.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that USANA Health Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 2/25/2025
• Today: 3/27/2025
• Next Earnings (Estimated): 4/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Personal Products
• Current Symbol: NYSE:USNA
• CIK: 896264
• Web: www.usana.com
• Phone: (801) 954-7100
• Fax: 801-954-7300
• Employees: 1,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +27.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.19
• Trailing P/E Ratio: 9.95
• Forward P/E Ratio: 11.49
• P/E Growth: 0.93
• Net Income: $63.79 million
• Net Margins: 6.30%
• Pretax Margin: 10.73%
• Return on Equity: 10.64%
• Return on Assets: 8.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.93
• Quick Ratio: 3.37

Sales & Book Value

• Annual Sales: $854.50 million
• Price / Sales: 0.62
• Cash Flow: $3.86 per share
• Price / Cash Flow: 7.29
• Book Value: $25.99 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 18,905,000
• Free Float: 18,997,000
• Market Cap: $532.18 million
• Optionable: Optionable
• Beta: 0.98